Iovance Biotherapeutics, Inc. Common Stock
Here’s whether Iovance Biotherapeutics, Inc. Common Stock (IOVA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+5.95% over 10 days); RSI 64 — healthy momentum range; strong 1-year return of +51.7%; 3-month momentum positive (+45.1%); rising volume confirms the move (1.22x 30d avg). Currently 11.5% off its 52-week high. Score: +8/7.
IOVA is in a confirmed uptrend, trading above both its 50-day ($4.18) and 200-day ($3.24) moving averages. An RSI of 63.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +51.7% compares to +16.5% for SPY (beat the market by 35.2%).